 |
|
|
|
February 2008 Cover
|
|
Health Canada has approved
the HIV/AIDS drug Isentress (raltegravir) for treatment-experienced
patients who show evidence of viral replication and drug resistance,
according to drug maker Merck Frosst.
Isentress is the first in
a new class of drugs called integrase inhibitors. It works by
blocking the integrase enzyme that HIV needs in order to insert its
DNA into the host cell's chromosome. Merck Frosst said the
approval to market the drug comes with conditions, pending results
of studies to verify its clinical benefit.
from
Canadian Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
